FAQs

Yes. Unlike broader cell therapy meetings such as those covering CAR‑T or T‑Cell Engager therapeutics, the TCR-Based Therapies Summit provides a specialized R&D forum exclusively focused on TCR modality development, including TCR discovery, target selection, HLA considerations, cross‑reactivity avoidance, and biologic‑based TCR engineering.

Yes. While general cell and gene therapy development conferences often feature large, multi‑track agendas, the 7th TCR Therapies Summit is a tightly focused, single‑track meeting designed for close‑knit interaction among TCR experts, enabling deeper discussion, targeted networking, and meaningful collaboration.

Yes. The 7th TCR-Based Therapies Summit features multiple new and unpublished data sessions, with presentations from leading biopharma innovators such as Immunocore, Eureka Therapeutics, and Zelluna Immunotherapy, offering exclusive insights from active clinical and translational programs.

Yes. The summit spans the full TCR therapeutic landscape—including TCR mimetics, TCR‑TCEs, TCR‑T products, and TCR bispecifics—addressing engineering strategies, specificity tuning, and next‑generation antigen targeting.

Yes. AI‑enabled approaches play a major role in the 2026 agenda, supporting advances in specificity prediction, affinity maturation, screening, and improved engineering decisions to accelerate TCR therapeutic development timelines.

Yes. Interactive workshops precede the main program, covering novel antigen discovery, non‑canonical target exploration, and advanced engineering strategies led by experts from organizations such as Enara Bio and T‑knife Therapeutics.

Yes. For organizations prioritizing TCR‑specific innovation, this summit provides far deeper modality‑targeted insights than broader CAR‑TCR or cell therapy events, making it the premier choice for teams developing next‑generation TCR therapeutics.

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Lorem ipsum dolor sit amet, consectetur adipiscing elit.